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ABSTRACT
Allogeneic hematopoietic stem cell transplantation (SCT) has recently been presented as promising immuno-
therapy against renal cell, colon, ovarian, breast, and primary liver cancer. Because clinical results demonstrate
a variable effect on metastases, we studied whether there is an association between the clinical response and
free cytokines in serum. Two patients with metastatic colorectal and 4 with renal cell cancer underwent
allogeneic SCT. Conditioning included fludarabine (30 mg/m2) for 3 or 5 days, using sibling or matched
unrelated donors, respectively, followed by 2 Gy total body irradiation (n 5) or cyclophosphamide (60 mg/kg)
for 2 days (n  1). Antithymoglobuline (4 mg/kg) was given to patients with matched unrelated donors (n  3).
Immunosuppression was cyclosporin A, combined with mycophenolate mofetil (n  5) or methotrexate (n  1).
The tumor load was examined by computer tomography of the thorax and abdomen before and 3, 6, 9, and 12
months after SCT. Free cytokines in serum were analyzed using enzyme-linked immunosorbent assay. In each
patient, the ratio between inflammatory (I) and anti-I cytokines was calculated. No statistical significance was
found between the cytokine ratio in correlation to the tumor load according to international response
evaluation criteria in solid tumors criteria. In contrast, tumor regression was found to correlate with domi-
nating I cytokine levels in 5/7 occasions, compared with 1/12 of cases with anti-I cytokines using our local
method focusing on metastases in lungs, lymph nodes, and liver (P  .01). Thus, an increased level of I
cytokines possibly mirrors tumor killing induced by type 1 T-cell response. Furthermore, anti-I cytokines
might inhibit cytotoxic cells from exerting the antitumor effect of allogeneic SCT.
© 2006 American Society for Blood and Marrow Transplantation
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sNTRODUCTION
Allogeneic hematopoietic stem cell transplanta-
ion (SCT) with nonmyeloablative or reduced inten-
ity conditioning (RIC) is one immunologic treatment
ith promising results to achieve reduction of tumors
upported by grants from the Swedish Cancer Society, the Swedish
hildren=s Cancer Society, the Swedish Research Council, the Stockholmcancer Foundation, and the Karolinska Institutet.
46n patients with metastatic solid cancer. A graft-ver-
us-leukemia effect has been demonstrated after SCT
n patients with myeloid and lymphoid leukemia, lym-
homa, and multiple myeloma [1-7]. A comparable
llogeneic graft-versus-tumor (GVT) effect has been
eported in metastatic breast cancer, colon cancer
CC), ovarian cancer, and renal cell cancer (RCC)
8-12]. The graft-versus-leukemia and GVT effects
eem to be mediated by alloreactive donor T lympho-
ytes recognizing target antigens on major histocom-
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Inflammatory Cytokines in Tumor Regression
Batibility complex class I of leukemic and tumor cells.
urthermore, donor lymphocyte infusion (DLI) is an
stablished posttransplantation immunotherapy with
ntitumor potential for both chronic myeloic leuke-
ia and metastatic RCC [3,10,12,13].
Childs et al. [10] presented the ﬁrst clinical study
n GVT effect on solid malignancy showing complete
r partial regression (R) of metastases at different
ocalizations in patients with RCC. Complete or par-
ial R of metastatic lesions has also been documented
n patients with CC, and breast, ovarian, prostate, and
onsmall-cell lung carcinoma [9,14-19]. Interestingly,
isparate responses of metastases in different localiza-
ions have been demonstrated in one patient with CC
nd two patients with RCC, who had progression in
he liver but R in the lungs [11].
There is evidence for involvement of inﬂamma-
ory (I) cytokines, especially tumor necrosis factor
TNF)-, as important mediators of graft-versus-host
isease (GVHD) [20]. Velardi et al [21] showed pro-
uction of interferon (IFN)-, another I cytokine, in
-cell clones isolated from patients with GVHD. Fur-
hermore, a recent study showed a moderate to severe
cute GVHD (aGVHD) with higher levels of TNF-
nd IFN-, but lower levels of interleukin (IL)-10 and
ransforming growth factor (TGF)-1, 2 weeks after
CT in patients with myeloid leukemia as compared
ith during the period of conditioning [22]. Different
ubsets of T-cell clones are responsible for cytokine
roduction. The type 1 T-cell response consists
ainly of IFN-, TNF-, and IL-2, which promote
ell-mediated responses and cytotoxicity. IL-4, -5, -6,
10, and -13 mediate a type 2 T-cell response, induc-
ng a speciﬁc humoral immunity that involves the
roduction of IgG1 and IgE.
In this study, we demonstrate an association be-
ween free cytokines in serum and variable response in
erms of tumor burden in 6 patients with solid cancer
fter RIC and SCT.
ATIENTS AND METHODS
atients
Six patients with metastatic solid tumors were in-
luded in the study: two patients had adenocarcinoma
n the colon (C4, C7) and 4 had RCC (R2, R4, R7,
13). Patients were treated with RIC and allogeneic
eripheral SCT at our institution between March
000 and August 2002. All 6 patients had been con-
idered to have tumors that were incurable with any
onventional therapy. All patients had undergone de-
ulking of the primary tumor, and in two patients,
eduction of metastases was also performed. Two pa-
ients had been given additional prior therapy, such as
ytostatics or interferon. The characteristics of the
atients are presented in Table 1. Our research ethics
ommittee approved the study.
B & M TT
a
P
a C C R R R R
C
y
*L
o
†p
347
Da
q
g
a
i
w
g
(
c
c
S
C
f
o
f
A
C
r
2
p
I
o
A
m
c
t
2
m
b
1
3
I
t
S
a
p
m
b
m
t
a
D
1
t
a
c
g
G
G
p
g
w
T
a
C
R. Conrad et al.
3onors
Patients and donors were HLA antigen typed with
high-resolution polymerase chain reaction-se-
uence-speciﬁc primers (SSP) method for HLA anti-
en classes I and II [23]. All donors were at least HLA
ntigen-A, -B and -DR1 compatible with the recip-
ent. An HLA antigen–identical sibling donor (n  3)
as given priority but, if not available, an HLA anti-
en–matched unrelated donor (n  3) was accepted
Table 1). From all donors, peripheral blood stem
ells were collected after stimulation with granulo-
yte-colony stimulating factor (Neupogen, Amgen,
tockholm, Sweden) [11].
onditioning
The RIC consisted of ﬂudarabine (30 mg/m2/d)
or 3 or 5 days, in HLA antigen–identical sibling donor
r matched unrelated donor, respectively (n  6),
ollowed by 2 Gy of total body irradiation (n  5).
ntithymocyte globulin (Thymoglobuline, Genzyme,
ambridge, Mass) (2 mg/kg/d) was given for 2 days to
ecipients with matched unrelated donor. After May
001, total body irradiation was replaced by cyclo-
hosphamide (60 mg/kg/d) for 2 days (n  1) [11,18].
mmunosuppression
Posttransplantation immunosuppression consisted
f cyclosporin A (Sandimmun Neoral, Novartis Pharma
G, Stein, Switzerland) in all patients for up to 3
onths. In addition, mycophenolate mofetil (Cell-
ept, Hoffman LaRoche, Basel, Switzerland) (0.5-1 g
wice a day) was given for 1 to 2 months. After May
able 2a. Status of Metastases Determined by Computer Tomography
nd Evaluation of Cytokines in Patients with Solid Tumor after Hemato
Patient CT, mon
Localization of Target Lesio
Lungs Lymph Nodes Adrenal G
C4 3
6
12
C7 3
6
9
12
R2 3 PD PD
6 PD PD
9 PD PD
12 PD PD
R4 3 PD PD
R7 3 PD NA
6 PR PR
9 PR PR
12 PR PR
R13 3 SD SD
6 SD SD
9 SD SD
T indicates computer tomography; gr, grade; GVHD, graft-vers
PR, partial response; Q, ratio between inﬂammatory and anti-inﬂamm
48001, mycophenolate mofetil (n  5) was replaced by
ethotrexate (n 1). The cyclosporin A doses ranged
etween 3 to 12 mg/kg/d to achieve a through level of
00 ng/mL in patients with a sibling donor, or 200 to
00 ng/mL in patients with an unrelated donor. Grade
aGVHD was treated with prednisolone (2 mg/kg/d)
o prevent more severe GVHD [11,18,24,25].
upportive Therapy and Treatment
The supportive therapy against bacterial, viral,
nd fungal infections was given according to the SCT
rotocol of the center [24,25]. Asymptomatic cyto-
egalovirus infection, diagnosed by testing peripheral
lood leukocytes for cytomegalovirus DNA by poly-
erase chain reaction, was treated with pre-emptive
herapy using ganciclovir by mouth or intravenously
ccording to an ongoing randomized study.
LIs
DLIs were given in escalating doses, 1, 5, 10, and
00  106 CD3 cells/kg recipient body weight. The
herapy usually started at 3 to 4 months after SCT and
fter the immunosuppressive therapy had been dis-
ontinued. The indications for DLI were tumor pro-
ression and/or mixed chimerism in the absence of
VHD (Table 1).
VHD
aGVHD was graded from 0 to IV according to
ublished criteria [26]. Chronic GVHD (cGVHD) was
raded as limited or extensive. aGVHD and cGVHD
ere diagnosed from the clinical symptoms and/or
g to the International Response Evaluation Criteria in Solid Tumors
Stem Cell Transplantation
Target
Lesions
Best Overall
Response Q
GVHD Acute/
ChronicLiver
PD PD PD >1
PD PD PD <1
SD SD SD >1 0/Lim
PD PD PD <1
PD PD PD <1
PD PD PD <1
PD PD PD <1
PD PD <1 gr I/0
PD PD >1 gr I/0
PD PD <1 0/Lim
PD PD >1
PD PD <1 gr I/0
PD PD <1
PR PD >1 gr II/0
PR PD <1 gr I/0
PR PR >1
SD PD <1 gr I/0
SD PD <1
SD PD >1 gr IV/0
t disease; Lim, limited; NA, not available; PD, progressive disease;accordin
poietic
ns
land
us-hos
atory cytokines; SD, stable disease.
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Inflammatory Cytokines in Tumor Regression
Biopsy specimens from skin, oral mucosa, liver, and
ut (Tables 1, 2a, and 2b).
valuation of Tumor Status
The tumor load was examined by computed to-
ography (CT) of the thorax and abdomen before
CT and 3, 6, 9, and 12 months after SCT (Tables 2a
nd 2b). Evaluation of tumor response was based on
wo methods, the international response evaluation
riteria in solid tumors (RECIST) [27] and our local
ethod [11,28].
According to RECIST, a partial response (PR) was
eﬁned as at least 30% decrease in the sum of the
ongest diameter of metastatic lesions compared with
umor load before SCT. Progressive disease (PD) in-
icated at least 20% increase in the same metastatic
esions or the appearance of one or more new lesions.
table disease (SD) was deﬁned as neither sufﬁcient
ecrease to qualify for PR nor sufﬁcient increase to
ualify for PD (Table 2a). Each CT examination was
ompared with the CT examination performed before
CT.
According to our local method, evaluation of tu-
or load was based both on the number and the size
f the metastatic lesions on CT. R, PD, and SD were
eﬁned separately for each metastatic localization
lung tissue, pleura, lymph nodes, and liver). R was
eﬁned as a decreased size of all metastases in the
ocalization relative to the tumor load before SCT or
revious CT examination. PD indicated increased tu-
or load or appearance of one or more lesions. SD
able 2b. Status of Metastases Determined by Computer Tomography
olid Tumor after Hematopoietic Stem Cell Transplantation
Patient CT, mon
Localization of Meta
Lungs
LymphTissue Pleura
C4 3 SD R R
6 SD PD S
12 SD SD S
C7 3 PD
6 SD
9 SD P
12 PD P
R2 3 PD
6 PD
9 PD
12 R
R4 3 PD P
R7 3 R PD S
6 R R R
9 SD PD P
12 SD SD S
R13 3 PD R
6 PD S
9 PD P
T indicates computer tomography; gr, grade; GVHD, graft-versus
Q, ratio between inﬂammatory and anti-inﬂammatory cytokineas deﬁned as neither sufﬁcient decrease to qualify for a
B & M Tnor sufﬁcient increase to qualify for PD. Based on
his local evaluation an assessment of the total meta-
tatic load was performed as follows: (1) if more than
r equal to 50% of metastatic localizations were char-
cterized as R, the total load was deﬁned as mixed
esponse (MR); (2) if at least one localization showed
D and at the same time all other localizations indi-
ated SD, the total load was deﬁned as PD; and (3) an
ndication of SD in all localizations lead to the total
ssessment of SD (Table 2b). Each CT examination
as compared with the nearest preceding CT exami-
ation.
ytokine Analyses
Blood samples were collected within 1 month be-
ore (n  6) and 1, 3, 6, 9, and 12 months after SCT
n  30). The compliance of sample collection was
8.9% (32/36). Fresh blood samples were centrifuged
nd the serum was frozen in aliquots at 20°C for
ater analysis. An automated chemiluminescence im-
unoassay (Immulite, DPC, Los Angeles, CA) was
sed for analyzing TNF- and IL-10 levels. IFN-
nd TGF-1 levels were determined by enzyme-
inked immunosorbent assay kits (Quantikine, R and
Systems, Minneapolis, Minn). Sensitivity of the
ssay for TNF-, IL-10, IFN-, and TGF-1 was 1.7,
.0, 8.0, and 7.0 pg/mL, respectively. Intra-assay co-
fﬁcient of variation was 3.2%, 3.1%, 3.4%, and
.3%, respectively. Cytokine analyses were performed
g to our Local Method and Evaluation of Cytokines in Patients with
Total
Assessment Q
GVHD Acute/
Chronics Liver
PD MR >1
PD PD <1
SD SD >1 0/Lim
PD PD <1
PD PD <1
PD PD <1
R PD <1
PD PD <1 gr I/0
PD PD >1 gr I/0
PD PD <1 0/Lim
PD MR >1
PD <1 gr I/0
PD PD <1
PD MR >1 gr II/0
SD PD <1 gr I/0
SD SD >1
MR <1 gr I/0
PD <1
PD >1 gr IV/0
isease; Lim, limited; MR, mixed response; PD, progressive disease;
gression; SD, stable disease.accordin
stases
Node
D
D
D
D
D
D
D
D
D
D
-host dccording to the manufacturer’s instructions.
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3tatistical Analysis
The 2-sided Fischer exact test was used to com-
are the cytokine balance to tumor response. All data
ere computed by using software (Statistica, Statsoft
nc., Tulsa, OK). P less than .05 was chosen to show a
tatistical signiﬁcant difference.
ESULTS
LIs
Of 6 patients, 5 were given DLIs (Table 1) after
ithdrawal of immunosuppressive treatment: one pa-
ient (R7) received one dose, one (R13) received two
oses, two (C7, R2) received 4 doses, and one patient
C4) received 5 doses of DLI (Figures 1 and 2). DLIs
ere administered between days 105 and 333 after
CT. One patient (R4) did not receive DLI because of
uctuating GVHD after SCT.
igure 1. Concentrations of I and A-I cytokines in patient (R2) wit
CC developed mild cGVHD after two episodes of aGVHD dur
TGF- and IL-10) cytokine concentrations developed toward dom
igure 2. Concentrations of I and A-I cytokines in patient (C7) w
ominated according to ratio between I (TNF- and IFN-) and A
ith progression of metastases.
50VHD
aGVHD, cGVHD, or both developed in 5 pa-
ients and was treated with corticosteroids in combi-
ation with cyclosporine with or without other immu-
osuppressive therapy. Two patients (R2, R13) had
GVHD grade I to II early (100 days) after SCT,
hich recurred as aGVHD or limited cGVHD after
LI (Figure 1, Tables 2a and 2b). One patient (C4)
ithout aGVHD developed limited cGVHD after
LI. One patient (R7) developed aGVHD before
eceiving DLI. One patient (R4) who did not receive
LI had early aGVHD that recurred as aGVHD.
umor Status and Cytokine Analyses
The tumor response after allogeneic SCT and
LI determined by CT is shown in Tables 2a and 2b.
For each patient, blood samples were analyzed for
cytokines, TNF-, and IFN-, and for anti-I (A-I)
RCC after allogeneic hematopoietic SCT. Patient with metastatic
t year after SCT. Ratio between I (TNF- and IFN-) and A-I
g I ones associated with R of the metastases.
ression of CC after allogeneic hematopoietic SCT. A-I cytokines
F- and IL-10) cytokine concentrations during ﬁrst year associatedh R of
ing ﬁrsith prog
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Inflammatory Cytokines in Tumor Regression
Bnes, TGF-1, and IL-10 (Figures 1 and 2). The ratio
etween I and A-I cytokines for each individual was
ompared with the tumor load (Tables 2a and 2b). A
atio of 1 or greater corresponded with I status, whereas
ratio less than 1 was associated with A-I status.
According to RECIST and using the evaluation of
arget lesions, 4/7 of occasions with PR or SD corre-
ated with I cytokines (Table 2a). This was compared
ith 3/12 of occasions where A-I cytokines were
ound with PR or SD. Thus, progressive status was
ound in 3 and 9 occasions with I and A-I, respectively
not signiﬁcant). If both target and nontarget lesions
ere evaluated for the best overall response according
o RECIST criteria, 2/7 of occasions with PR or SD
orrelated with I cytokines (Table 2a). None of 12
ccasions with PR or SD was found with dominating
-I cytokines. Thus, progressive status was found in 5
nd 12 occasions with I and A-I, respectively (not
igniﬁcant).
According to our local method, we found MR or
D in 5/7 of occasions correlated with I cytokines
Table 2b). This was compared with 1/12 of evalua-
ions where A-I cytokines were found with MR or SD.
hus, progressive status was found in 2 and 11 occa-
ions with I and A-I, respectively (P  .01).
ISCUSSION
Allogeneic hematopoietic SCT is a promising im-
unotherapy for patients with metastatic solid cancer
8-12]. However, clinical experience has demonstrated
variable antitumor effect on metastases in different
rgan localizations [10,11]. Despite tumor R that was
een in some metastatic lesions and at some time, the
VT effect was only transient. Therefore, additional
mmunotherapy seems to be needed to control tumor
rowth. Other tumor load reducing tools such as ste-
eotactic irradiation and radiofrequency ablation should
lso be taken into account. Especially in the liver,
etastases are difﬁcult to control and the reason
ight involve escape mechanisms of metastases. Ac-
ording to our evaluation method, all patients but one,
ho were classiﬁed as MR, had PD in the liver,
hereas in all other localizations R or SD were found.
his is in accordance with previous ﬁndings on un-
atisﬁed tumor response on liver metastases in parallel
ith an antitumor effect in other localizations in pa-
ients with metastatic RCC, CC, and melanoma
11,29,30]. The liver metastases probably need addi-
ional treatment, such as DLI by the hepatic artery
ith or without radiofrequency ablation therapy [30].
delayed immunologic metastases reducing effect on
he tumor in patients with breast cancer, RCC, and
varian cancer has been reported 6 months after SCT
8,10,14,15].In this study according to RECIST, no statistical m
B & M Tigniﬁcance was found between the ratio of I and A-I
ytokines as correlated with the tumor load. In con-
rast, according to our local method, we show, to our
nowledge for the ﬁrst time, a correlation between
VT effect and free cytokines in serum. Tumor R was
ound to correlate with I cytokine levels in 5/7 of
ccasions, which was statistically signiﬁcant, if com-
ared with 1/12 of occasions with predominating A-I
ytokines.
The RECIST criteria might not be applicable to
ur patients. It is appropriate for solid tumor patients,
here the main emphasis is on the effect of chemo-
adiotherapy with necrotic cells as a result of the
reatment. In allogeneic SCT, however, the transplan-
ation is applied as an immunotherapy. We, therefore,
re more interested in immunologic effects, which are
elayed in comparison with other traditional antican-
er treatments. The patient’s new immune system
evelops slowly allowing late R of metastases [31].
There are both advantages and disadvantages with
ECIST and our local method, respectively. One
isadvantage of RECIST is the possibility to choose
etween the evaluation of target lesions or evaluation
f both target and nontarget lesions (i.e., the best overall
esponse). Another disadvantage with RECIST is the
hoice of the 5 largest metastases per organ (and 10
argest in total), which implies that smaller metastases
n other organs are missed. Therefore, in some pa-
ients, the evaluation of the largest target lesions may
ccur only in one organ totally passing the changes of
ther metastases (e.g., patients C4 and C7; Table 2a).
n contrast, our local method includes 4 main meta-
tatic localizations independent of their initial size.
urthermore, an appearance of a new metastasis inde-
endently of the organ localization will be evaluated as
D using RECIST, despite the R of other metastases
n the same or other organs (e.g., patient R2). Our
valuation method mirrors the dynamics of the me-
astases over time because it compares the changes
ith the previous CT examination instead of with the
retransplantation one as according to RECIST (e.g.,
atient R7).
Secretion of TNF- and IFN- from the recipi-
nt’s activated T and natural killer cells occurs as early
s during conditioning before SCT [20,22]. Donor T
ells of the graft, activated by antigen-presenting cells
f the host, will augment this I cytokine production
32]. Upon donor T-cell activation, HLA antigen
lasses I and II or minor histocompatibility antigen
ifferences stimulate CD8 and CD4 T cells creat-
ng the platform for GVHD. These T-cell popula-
ions also mediate the graft-versus-leukemia/GVT ef-
ect with or without association to HLA antigen,
lthough the association to minor histocompatibility
ntigen may be stronger [33,34]. In mouse and human
tudies on GVHD and GVT, cytokine (TNF-, IL-1)
ediated toxicity and antitumor effect, respectively,
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3ere associated with host antigen-presenting cells
lone, without requiring alloantigen presentation on
ost target cells [34,35]. Visentainer et al. [36] reported
igher levels of TNF- in patients with leukemia and
GVHD than those without, 2 weeks and 2 months
fter SCT. Similarly, increased amounts of serum cy-
okines TNF- and IFN- were found in 3 of our 6
atients in association with conditioning and aGVHD
arly after SCT (patients R2, R7, R13).
Elevated TNF- and IFN- levels found in this
tudy toward the end of the ﬁrst year after SCT may
ontribute to an antitumor effect and are in line with
bservations in animals and human beings. Mice de-
cient in IFN- and IFN- receptor, or cytokines
L-13 and IL-23, which stimulate IFN- production,
re more sensitive to carcinogens and show enhanced
umor development as compared with normal mice
37]. Double-knockout mice lacking T and B cells, and a
ranscription factor required for IFN- signaling,
pontaneously develop adenocarcinomas of the colon,
reast, and lung. IFN- may contribute to an antitu-
or effect, as it can up-regulate major histocompati-
ility complex class I expression in the tumor, cata-
yzing an immune response [37]. Thus, an increased
umor development mediated by IFN- deﬁciency
ay occur because of diminished control of target cell
rowth and apoptosis. An increased TNF- produc-
ion has been found in association to successful che-
otherapy of patients with colorectal cancer [38]. In
ddition, DLI containing natural killer and T cells
ay contribute to an antitumor effect by enhanced
FN- production as was seen in some of our patients
ho showed R of metastases after DLI.
Elevated levels of TGF-1 protein in serum and
GF-1 messenger RNA in tumor tissue of colorectal
ancer were correlated with disease progression [39].
n addition, increased levels of TGF-1 in serum, in
ombination with a reduced amount of circulating
endritic cells, were found in patients with colorectal
ancer [40]. This might mirror decreased antigen pre-
entation and immune activation. Patients with breast,
ung, prostate, ovarian, colon, and hepatocellular car-
inoma have been shown to have elevated TGF-1
evels in plasma in connection with loss of response to
GF-1 as a growth inhibitor [41]. Several in vivo
odels of breast and prostate cancer have demon-
trated a connection between up-regulated TGF-1
xpression and enhanced tumorigenicity, increased
issue invasion, and drug resistance. Secretion of
GF-1 from malignant cells suppresses immune re-
ponses against the tumor growth and enhances an-
iogenesis by signaling to nontransformed stroma
ells in the tumor [41]. Decreased serum levels of
GF-1 have been found in patients with leukemia in
ssociation with aGVHD after engraftment of hema-
opoietic SCT. Maintaining this immunologic status
ould be in line with the allogeneic antileukemia
52ffect. Serum TGF-1 levels were accordingly low in
ur patients early after conditioning and during
GVHD. In contrast, patients whose tumor load con-
inued to increase had increased TGF-1 levels.
Another immunosuppressive cytokine, IL-10, re-
uces the antigen-presenting capacity of antigen-pre-
enting cells and is present in large amounts in tumor
iopsy specimens from patients with ovarian cancer
42]. IL-10 inhibits IFN- synthesis, production of
NF-, and IL-1, and type 1 T cells differentiation in
he mouse model. Furthermore, this cytokine sup-
resses T-cell mediated lysis by down-regulating ma-
or histocompatibility complex class I expression on
umor cells [43]. The levels of IL-10 have shown to
ncrease up to 4 months after SCT in patients with
eukemia who develop aGVHD [44]. This may reﬂect
n attempt by the immune system to control the
mmune reaction.
In this article, we describe the mass effect of cy-
okines by calculating a ratio between I and A-I cyto-
ines. This ratio mirrors the immune response against
umor growth mediated by various activation levels
f types 1 and 2 T-cell populations, and is in line with
he same mechanism suggested for GVHD by Visen-
ainer et al. [36]. One should take into account the
inetics of these cytokines over time (i.e., the ratio
easured at each time point) would be expected to
redict the developing immune response to allogeneic
CT, which would be measured some weeks or
onths later using CT assay. Serial cytokine analyses
re recommended to guide the early tapering of im-
une suppressive therapy. Later this monitoring
ight be useful to guide infusion of donor lympho-
ytes or adoptively transferred tumor speciﬁc T or
atural killer cells of stem cell donor origin to inten-
ify the antitumor effect after allogeneic SCT against
olid cancer.
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